Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2].
Molecular Weight:
148000 (average)
Purity:
99.74
CAS Number:
[1018448-65-1]
Target:
Antibody-Drug Conjugates (ADCs),EGFR
Application Notes:
ADC Related
* VAT and and shipping costs not included. Errors and price changes excepted